Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Merck & Company (MRK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 164,952,896
  • Shares Outstanding, K 2,696,190
  • Annual Sales, $ 40,122 M
  • Annual Income, $ 2,394 M
  • 36-Month Beta 0.76
  • Price/Sales 4.13
  • Price/Cash Flow 10.85
  • Price/Book 4.93

Price Performance

See More
Period Period Low Period High Performance
1-Month
58.03 +5.94%
on 05/29/18
62.96 -2.37%
on 06/13/18
+3.02 (+5.17%)
since 05/22/18
3-Month
52.83 +16.35%
on 04/03/18
62.96 -2.37%
on 06/13/18
+7.35 (+13.58%)
since 03/22/18
52-Week
52.83 +16.35%
on 04/03/18
66.41 -7.44%
on 09/18/17
-4.55 (-6.89%)
since 06/22/17

Most Recent Stories

More News
Merck Presents New Data from the Comparative Trials with Sitagliptin (CompoSIT) Clinical Trial Program with JANUVIA(R) (sitagliptin)

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data from the Comparative Trials with Sitagliptin (CompoSIT) clinical trials with JANUVIA(R) (sitagliptin)....

MRK : 61.47 (+0.47%)
Bristol-Myers' BLA for Opdivo Label Expansion Accepted by FDA

Bristol-Myers Squibb Company (BMY) announces that the FDA accepts its supplemental Biologics License Application (sBLA) for the label expansion of its blockbuster immuno-oncology drug Opdivo.

AGLE : 10.72 (+2.29%)
MRK : 61.47 (+0.47%)
RHHBY : 27.7700 (+2.51%)
BMY : 55.14 (+2.22%)
Merck Animal Health, AVMF Announce Veterinary Student Innovation Award Winners

Merck Animal Health, in partnership with the American Veterinary Medical Foundation (AVMF), recently announced the winners of the 2018 Veterinary Student Innovation Awards.

MRK : 61.47 (+0.47%)
Look for Shares of Merck & Co to Potentially Pullback after Yesterday's 1.15% Rise

Merck & Co (NYSE:MRK) traded in a range yesterday that spanned from a low of $61.22 to a high of $61.92. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $61.48...

MRK : 61.47 (+0.47%)
SmarTrend Watching for Potential Pullback in Shares of Merck & Co After 1.15% Gain

Merck & Co (NYSE:MRK) traded in a range yesterday that spanned from a low of $61.22 to a high of $61.92. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $61.48...

MRK : 61.47 (+0.47%)
Merck (MRK) Stock Up So Far This Year on Keytruda Strength

Merck's shares are up 8.4% this year driven by strong performance and positive regulatory updates related to its PD-1 inhibitor, Keytruda.

AZN : 35.06 (-0.26%)
MRK : 61.47 (+0.47%)
LLY : 85.92 (-0.17%)
AMGN : 185.15 (-0.45%)
Incyte (INCY) Announces Positive Results on Jakafi for GVHD

Incyte (INCY) reports positive results on Jakafi from the REACH trial for the indication of acute GVHD. The company plans to file a sNDA for the drug in the third quarter.

MRK : 61.47 (+0.47%)
LLY : 85.92 (-0.17%)
INCY : 74.03 (+2.12%)
NVS : 75.06 (+1.46%)
TESARO (TSRO) Stock Up on Rumors of Buyout Offer From Roche

Shares of TESARO (TSRO) rise on speculation of an acquisition bid from Roche.

FMI : 136.70 (+0.22%)
MRK : 61.47 (+0.47%)
TSRO : 49.62 (+8.46%)
RHHBY : 27.7700 (+2.51%)
Myriad Genetics Wins FDA SPMA Nod for BRACAnalysis CDx

The FDA accepts Myriad Genetics' (MYGN) supplementary premarket approval (sPMA) application for BRACAnalysis CDx to identify the best responders to Pfizer's PARP inhibitor, talazoparib.

AZN : 35.06 (-0.26%)
MRK : 61.47 (+0.47%)
MYGN : 38.87 (+0.47%)
PFE : 36.51 (+0.58%)
ImmunoGen's Lead Candidate Gets Fast Track for Ovarian Cancer

With ImmunoGen's (IMGN) lead pipeline candidate, mirvetuximab soravtansine getting Fast Track designation in the United States, its development and review are likely to get expedited.

AGLE : 10.72 (+2.29%)
MRK : 61.47 (+0.47%)
IMGN : 12.15 (+4.02%)
RHHBY : 27.7700 (+2.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade MRK with:

Business Summary

Merck & Co., Inc., a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through their prescription medicines, vaccines, biologic therapies...

See More

Key Turning Points

2nd Resistance Point 62.24
1st Resistance Point 61.85
Last Price 61.47
1st Support Level 61.15
2nd Support Level 60.84

See More

52-Week High 66.41
Last Price 61.47
Fibonacci 61.8% 61.22
Fibonacci 50% 59.62
Fibonacci 38.2% 58.02
52-Week Low 52.83

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar